Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 4, 2009, Pages 263-271

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; Immunomodulatory drugs; Tumor lysis syndrome

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; BENDAMUSTINE; CALCIUM; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLAVOPIRIDOL; FLUDARABINE; FUROSEMIDE; GLUCONATE CALCIUM; GLUCOSE; IMMUNOMODULATING AGENT; INSULIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; MANNITOL; MONOCLONAL ANTIBODY; PHOSPHATE; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PURINE DERIVATIVE; RASBURICASE; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; URIC ACID;

ALKALINITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; DEATH; DEFIBRILLATOR; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DIURESIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; HEART ARRHYTHMIA; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SEIZURE; THERAPY DELAY; TREATMENT OUTCOME; TUMOR CELL; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TUMOR LYSIS SYNDROME;

EID: 66349138551     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61-68.
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.
3. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007;33:397-407.
4. Gobel BH. Management of tumor lysis syndrome: prevention and treatment. Semin Oncol Nurs. 2002;18:12-16.
5. Cairo MS, Coenelis M, Baruchel A, et al. Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):Abstract 17006.
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
7. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
8. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111:4916-4921.
9. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53.
10. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
11. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
12. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol. 1998;16:2313-2320.
13. Ramachandran A, Majumdar G. Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia. Hematol J. 2004;5: 528-529.
14. Cheson BD, Rummel MJ. Bendamustine: Rebirth of an old drug. J Clin Oncol. 2009 Feb 17 [Epub ahead of print]
15. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B-cell chronic lymphocytic leukemia: An updated analysis from an international phase III study. Blood (ASH Annual Meeting Abstracts). 2007;110: Abstract 2091.
16. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL study group. Haematologica. 2005;90:1357-1364.
17. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.
18. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
19. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 1999;62:76-82.
20. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
21. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
22. Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006;106:2412-2420.
23. Nikitin A, Stadnik A, Salogub N, et al. Retrospective comparison of efficasy and toxicity of FC and FCR regimens in untreated patients with B-cell chronic lymphocytic leukemia. Hematologica. 2008;93(suppl 1):Abstract 95.
24. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and Rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2008;112: Abstract 325.
25. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89-91.
26. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62:247-250.
27. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
28. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176-4181.
29. Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005;29:1253-1257.
30. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
31. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-1552.
32. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
33. Chanan-Khan A, Miller KC, Whitworth A, et al. Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymphoma. 2007;48(suppl 1): S166.
34. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
35. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5047.
36. Andritsos LA, Johnson AJ, Blum W, et al. Unacceptable toxicity of lenalidomide when administered to CLL patients at higher doses. Blood (ASH Annual Meeting Abstracts). 2007;110: Abstract 4727.
37. Chen CI, Paul H, Mariela P, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood. 2007;110: Abstract 2042.
38. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93:1877-1885
39. Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol. 2005;3:54-61.
40. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica. 2008;93:9-13.
41. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol. 2005;3:117-124.
42. Zojer N, Ludwig H. Hematological emergencies. Ann Oncol. 2007;18(suppl 1):i45-i48.
43. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007;4:83-93.
44. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97:2998-3003.
45. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697-704.
46. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048-1054.
47. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21:4402-4406.
48. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002;13:789-795.
49. Mayne N, Keady S, Thacker M. Rasburicase in the prevention and treatment of tumour lysis syndrome. Intensive Crit Care Nurs. 2008;24:59-62.
50. Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. Blood Cell Mol Dis. 2009 [Epub ahead of print]
51. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta. 2003;333:13-18.
52. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.
53. Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994;8:351-353.
54. Heney D, Essex-Cater A, Brocklebank JT, Bailey CC, Lewis IJ. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol. 1990;4:245-247.
55. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.